Immune enhancers composed of polyvalent binding sites of anti-CD3 antibodies.
Anti-CD3 antibodies of some IgG subclasses are very potent T lymphocyte mitogens in vitro and, seemingly contradictorily, very effective immunosuppressive agents in vivo. Using hamster anti-murine CD3 monoclonal antibody, 2C11, as a model, we have found that 2C11.IgG, or its F(ab')2 fragment, coupled to microbeads can provide short-term and vigorous activation of T cells and expansion of the lymphoid system in vivo. In contrast to free 2C11.IgG, these conjugates do not kill mice and cause T cell depletion, and can enhance immune responses. This study suggests that properly modified anti-CD3 antibodies can serve as in vivo immune system enhancers potentially useful in the treatment of cancer and chronic infectious diseases.
Wedrychowski
A
A
Tanox Biosystems, Inc., Houston, TX 77025.
Kim
Y W
YW
Chang
T W
TW
D000818:Animals; D000917:Antibody Formation; D001666:Binding Sites, Antibody; D017252:CD3 Complex / Q000276:immunology*; D006224:Cricetinae; D007109:Immunity; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008863:Microspheres; D013601:T-Lymphocytes / Q000276:immunology*
D017252:CD3 Complex; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G